Kephera Diagnostics, based in Framingham, MA, develops rapid point-of-care immunoassay tests for infectious diseases including Chagas disease and hookworm.

Regene, based in Belchertown, MA, develops anti-aging and Alzheimer's-focused therapies targeting molecular aging mechanisms.

Pearl Bio is a biotechnology company focused on genome engineering, ribosome engineering, and biomanufacturing. The company was founded by Farren Isaacs, an Associate Professor at Yale University who has pioneered technologies for genome and RNA engineering to construct organisms and produce novel chemicals, proteins, and materials for applications in biotechnology, materials science, and medicine.

Absco Therapeutics is a biopharmaceutical company developing drug delivery technologies using thermogelling polymers that transform from liquid to solid at body temperature to create controlled-release depots for immune-modulating therapies. The company's lead program, ABS005, is a non-surgical treatment candidate for cervical intraepithelial neoplasia (CIN2/3) that combines a clinically validated drug with the company's polymer system for sustained intralesional delivery.

Accelerated Muscle Biotechnologies (AMB) is a contract research organization that provides access and support to muscle researchers, specializing in physiological structure-function characterization through muscle functional assays and small-angle X-ray diffraction. The company operates laboratories in Boston and Hamburg, conducting muscle X-ray diffraction experiments and muscle fiber experimentation for clients and collaboration partners at synchrotron facilities worldwide.

Cambridge, MA precision-medicine company developing AI-powered, biomarker-guided miniaturized biosensors for point-of-care cancer diagnostics, including bladder cancer detection.

Lexington, MA biotech developing an inhalable engineered oncolytic virus, based on influenza A, to treat metastatic non-small cell lung cancer and other lung metastases.

Cambridge, MA preclinical biotech using Harvard-patented acoustophoretic fluid-processing technology to formulate biologic drugs into ultra-high-concentration, small-volume injections.

INSUFFICIENT The page content provided is primarily a contact page with header navigation, company name, tagline, and contact details, but lacks substantive information about the company's actual products or services beyond the vague tagline "Accelerating early-stage drug discovery."

Boston, MA company building bead-assisted mass spectrometry tools for targeted proteomics, including multiplexed cell-signaling and Alzheimer's biomarker assays.

Builds affordable on-site soil testing tools, addressing the link between contaminated soil, the food supply, and children's neurological development.

Akamai operates one of the world's largest content delivery networks (CDN), alongside cloud security and edge computing services.

Aldatu Biosciences develops molecular diagnostic assays using its proprietary PANDAA (Pan Degenerate Amplification and Adaptation) platform to detect infectious diseases including SARS-CoV-2, HIV drug resistance, and viral hemorrhagic fevers through RT-PCR technology. The company's technology is designed to detect pathogens in genomically variable regions without requiring assay redesign when new viral variants emerge.

Natick, MA company developing sensor, signal-processing, and AI technologies for human physiology, including voice-therapy assessment tools and AR-based rehabilitation platforms.

Alzheon is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative disorders, with a Phase 3 program for Alzheimer's disease based on an anti-aggregation mechanism. The company's lead program, valiltramiprosate (ALZ-801), is an oral anti-amyloid oligomer inhibitor being tested in early Alzheimer's disease and mild cognitive impairment, while a second clinical-stage program (ALZ-507) targets Alzheimer's disease prevention.

Massachusetts diagnostics company developing a point-of-care nucleic acid amplification test platform for rapid molecular testing, including a multiplex respiratory panel.

Telehealth platform (American Well Corporation). HQ Boston, MA. Blue Heron Capital exited investment (invested 2018, exited via IPO).

The Amyloidosis Research Consortium (ARC) is a nonprofit organization that provides patient support, education, and resources for people with amyloidosis while funding and coordinating research initiatives to advance treatment options. ARC offers webinars, clinical trial information, a patient-provider communication tool called My Amyloidosis Pathfinder, and guidance specific to different amyloidosis types including AL, hereditary ATTR, and wild-type ATTR amyloidosis.

Lunenburg, MA nanotechnology R&D firm developing high-performance particle and radiation detector technology under NIH SBIR funding.

Allston, MA biotech building a single-cell proteomics and spatial-profiling platform that measures protein expression on tumor and immune cells to explain drug failure and response.